A

Allurion Technologies Inc. (ALUR)

OQB – Real vaqt narxi. Valyuta: USD

0.80

+0.09 (12.83%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

A

Allurion Technologies Inc. (ALUR)

OQB – Real vaqt narxi. Valyuta: USD

0.80

+0.09 (12.83%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.03.2026

Allurion Advances Plan to Regain Listing Compliance

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (the “Company”) (OTCID: ALUR), a pioneer in metabolically healthy weight loss, announced today that it has appealed the decision by the New York Stock Exchange (the “NYSE”) to initiate delisting proceedings against Allurion's securities pursuant to Section 802.01B of the NYSE's Listed Company Manual, which requires listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least.

11.03.2026

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced that it has officially begun training and on‑boarding partner accounts across the United States, including large academic medical centers and private practices. The company has begun manufacturing FDA-approved product and expects to begin shipping in April. This milestone represents a pivotal step in the company's commercial expansion into the world's larges.

06.03.2026

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities enumerated below (“Securities”) of Allurion Technologies, Inc. (the “Company”) from the NYSE. NYSE Regulation reached its decision to commence proceedings to delist the Company's Securities pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company had fallen below the NYSE's.

02.03.2026

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million in stockholders' equity or (ii) at le.

02.03.2026

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities enumerated below (“Securities”) of Allurion Technologies, Inc. (the “Company”) from the NYSE. Trading in these Securities will continue on the NYSE until such time as described below. Symbol Description ALUR Common stock, par value $0.0001 per share ALUR WS Warrants to purchase 0.056818 shares of com.

27.02.2026

Are Medical Stocks Lagging Allurion Technologies, Inc. (ALUR) This Year?

Here is how Allurion Technologies, Inc. (ALUR) and McKesson (MCK) have performed compared to their sector so far this year.

24.02.2026

Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Wa.

Videolar

No Data

There is no data to display

Press-relizlar

12.03.2026

Allurion Advances Plan to Regain Listing Compliance

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (the “Company”) (OTCID: ALUR), a pioneer in metabolically healthy weight loss, announced today that it has appealed the decision by the New York Stock Exchange (the “NYSE”) to initiate delisting proceedings against Allurion's securities pursuant to Section 802.01B of the NYSE's Listed Company Manual, which requires listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least.

11.03.2026

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced that it has officially begun training and on‑boarding partner accounts across the United States, including large academic medical centers and private practices. The company has begun manufacturing FDA-approved product and expects to begin shipping in April. This milestone represents a pivotal step in the company's commercial expansion into the world's larges.

06.03.2026

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities enumerated below (“Securities”) of Allurion Technologies, Inc. (the “Company”) from the NYSE. NYSE Regulation reached its decision to commence proceedings to delist the Company's Securities pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company had fallen below the NYSE's.

02.03.2026

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million in stockholders' equity or (ii) at le.

Search stocks

Allurion Technologies Inc. (ALUR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Allurion Technologies Inc. (ALUR)

Allurion Advances Plan to Regain Listing Compliance

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

Are Medical Stocks Lagging Allurion Technologies, Inc. (ALUR) This Year?

Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

Videolar

No Data

Press-relizlar

Allurion Advances Plan to Regain Listing Compliance

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE